Translation of "Pharmaceutical scale " (English → French) :

chemist's balance | pharmaceutical balance | pharmaceutical scale | pharmacy balance

pharmaceutical product [ disinfectant | pharmaceutical preparation | pharmaceutical speciality ]

pharmaceutical legislation [ control of medicines | pharmaceutical regulations ]

pricing of medicines [ P&R policy | pharmaceutical pricing and reimbursement | pharmaceutical pricing policy | pharmaceutical reimbursement and pricing policy | pricing and reimbursement of medicinal products ]

designing pharmaceutical manufacturing systems | pharmaceutical production systems designing | design pharmaceutical manufacturing systems | pharmaceutical manufacturing systems design

give specialist pharmaceutical advice | give specialist pharmaceutical advices | offer specialist pharmaceutical advice | provide specialist pharmaceutical advice

pharmaceutical production facilities construction supervising | supervising pharmaceutical production facilities construction | manage pharmaceutical production facilities construction | managing pharmaceutical production facilities construction

dosage form | pharmaceutical dosage form | pharmaceutical dose form | pharmaceutical form

Federal/Provincial/Territorial Working Group on Pharmaceutical Issues [ FPTWG-PI | F/P/T Working Group on Pharmaceutical Issues | F/P/T Pharmaceutical Issues Working Group | Working Group on Pharmaceutical Issues ]

japanese fruit scale | mulberry scale | oleander scale | papaya scale | west indian peach scale | white peach scale

61. Considers marine- and ocean-related biotechnology to be a highly diversified sector which, taken as a whole, has immense potential from the point of view of engendering and applying new knowledge and creating new products and processes with high added value (new materials, foods, pharmaceutical ingredients, etc.); draws attention to the education and training requirements related to this sector, implying a need for Member States to shoulder a large measure of responsibility together with the private sector, and for international cooperation to be pursued on a similarly comprehensive scale ...[+++];

61. Considers marine- and ocean-related biotechnology to be a highly diversified sector which, taken as a whole, has immense potential from the point of view of engendering and applying new knowledge and creating new products and processes with high added value (new materials, foods, pharmaceutical ingredients, etc.); draws attention to the education and training requirements related to this sector, implying a need for Member States to shoulder a large measure of responsibility together with the private sector, and for international cooperation to be pursued on a similarly comprehensive scale ...[+++];

61. Considers marine- and ocean-related biotechnology to be a highly diversified sector which, taken as a whole, has immense potential from the point of view of engendering and applying new knowledge and creating new products and processes with high added value (new materials, foods, pharmaceutical ingredients, etc.); draws attention to the education and training requirements related to this sector, implying a need for Member States to shoulder a large measure of responsibility together with the private sector, and for international cooperation to be pursued on a similarly comprehensive scale ...[+++];

(Return tabled) Question No. 199 Ms. Kirsty Duncan: With regard to the development and operation of the Canadian Multiple Sclerosis Monitoring System (CMSMS) announced in March 2011: (a) what are the government's baseline assumptions for the CMSMS, (i) how many Canadians live with MS according to the government’s source, (ii) what is the government's source; (b) what have been the challenges in developing the system between March 2011 and today, (i) how has each challenge been overcome, (ii) what are the achievements to date, (iii) what milestones has the government planned between December 2013 and December 2015 and by what dates; (c) what is the cost of developing the system, broken down by costs to date; (d) how much money did the Can ...[+++]adian Institutes for Health Research (CIHR) contribute to the development of the CMSMS, (i) were there any other partners involved in the development of the system, (ii) if so, who are they, (iii) what has each contributed; (e) who was involved in the design and development of the CMSMS, (i) from what departments/institutions were they, (ii) were potential conflicts of interest declared and, if so, how; (f) what health information does the CMSMS track, specifically, with regard to (i) chronic cerebrospinal venous insufficiency (CCSVI), (ii) impacts of CCSVI treatment, including but not limited to use of the following scales, Expanded Disability Status Scale, Modified Fatigue Impact Scale, Multiple Sclerosis Impact Scale, and Multiple Sclerosis Quality of Life Inventory, (iii) pharmaceutical treatments for MS, (vi) adverse drug reactions by MS drug; (g) who is/was overseeing pilot testing, (i) who is/was responsible for ensuring that patient information is/was protected, (ii) who is/was responsible for the integrity of the results; (h) were ethical reviews for pilot testing necessary and, if so, on what date did each pilot site pass ethical review; (i) when is pilot testing expected to/did it take place and at which MS clinics ...